Study Type–Therapy (cohort) Level of Evidence 2a What's known on the subject? and What
does the study add? Despite expanding treatment options for castration‐resistant prostate …

What's known on the subject? and What does the study add? Castration resistance has
been appreciated for decades, and several mechanisms theorising on this effect have been …

Abstract Context Prostate cancer (PCa) is the most common noncutaneous malignancy and
the second leading cause of cancer mortality amongst men in the Western world. Up to 40 …

CONTEXT: Castration-resistant prostate cancer (CRPC) refers to patients who no longer
respond to surgical or medical castration. Standard treatment options are limited …

BACKGROUND The mammalian target of rapamycin (mTOR) pathway is up‐regulated in
castration‐resistant prostate cancer (CRPC). Nevertheless, inhibition of mTOR is ineffective …

Medical oncologists who treat men with castration-resistant prostate cancer (CRPC) have
seen an abundance of new agents approved by the United States Food and Drug …

Background Non-metastatic castration resistant prostate cancer (M0CRPC) is a
heterogenous disease state affecting an estimated 100,000 men in the United States …

BACKGROUND Most prostate cancer‐related deaths occur in patients with castration‐
resistant prostate cancer (CRPC). Recent preclinical and clinical studies have identified …

Background This study investigated the safety, pharmacokinetics (PK) and clinical antitumor
activity of ABT-751, a novel sulfonamide antimitotic and vascular disrupting agent, in …

Materials and methods A systematic literature review was conducted via electronic database
articles based on title, abstract, study format, and content. The majority of selected articles …